Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. 2001

J A Menéndez, and M del Mar Barbacid, and S Montero, and E Sevilla, and E Escrich, and M Solanas, and H Cortés-Funes, and R Colomer
Division of Medical Oncology, Hospital Universitario 12 de Octubre, Avda. de Córdoba Km 5.4, E-28041 Madrid, Spain.

It has been suggested that dietary interventions may improve the effectiveness of cancer chemotherapy. We have examined the combined in vitro cytotoxicity of paclitaxel and the fatty acids gamma-linolenic acid (GLA, 18:3n-6) and oleic acid (OA, 18:1n-9) in human breast carcinoma MDA-MB-231 cells. The effect of fatty acids on paclitaxel chemosensitivity was determined by comparing IC(50) and IC(70) (50 and 70% inhibitory concentrations, respectively) obtained when the cells were exposed to IC(50) and IC(70) levels of paclitaxel alone and fatty acids were supplemented either before or during the exposure to paclitaxel. The 3-4,5-dimethylthiazol-2-yl-2,5-diphenyl-tetrazolium bromide (MTT) assay was used to determine cell growth inhibition. GLA by itself showed antiproliferative effects, and a possible GLA-paclitaxel interaction at the cellular level was assessed by the isobologram and the combination-index (CI) methods. Isobole analysis at the isoeffect levels of 50 and 70% revealed that drug interaction was predominantly synergistic when GLA and paclitaxel were added concurrently for 24 h to the cell cultures. Interaction assessment using the median-effect principle and the combination-index (CI) method showed that exposure of MDA-MB-231 cells to an equimolar combination of concurrent GLA plus paclitaxel for 24 h resulted in a moderate synergism at all effect levels, consistent with the results of the isobologram analysis. When exposure to GLA (24 h) was followed sequentially by paclitaxel (24 h) only an additive effect was observed. The GLA-mediated increase in paclitaxel chemosensitivity was only partially abolished by Vitamin E, a lipid peroxidation inhibitor, suggesting a limited influence of the oxidative status of GLA in achieving potentiation of paclitaxel toxicity. When OA (a non-peroxidisable fatty acid) was combined with paclitaxel, an enhancement of chemosensitivity was found when OA was used concurrently with paclitaxel, although less markedly than with GLA. Pretreatment of MDA-MB-231 cells with OA for 24 h prior to a 24 h paclitaxel exposure produced greater enhancement of paclitaxel sensitivity at high OA concentrations than the concurrent exposure to OA and paclitaxel. The OA-induced sensitisation to paclitaxel was not due to the cytoxicity of the fatty acid itself. When these observations were extended to three additional breast carcinoma cell lines (SK-Br3, T47D and MCF-7), simultaneous exposure to GLA and paclitaxel also resulted in synergism. GLA preincubation followed by paclitaxel resulted in additivity for all cell lines. Simultaneous exposure to paclitaxel and OA enhanced paclitaxel cytotoxicity in T47D and MCF-7 cells, but not in SK-Br3 cells, whereas preincubation with OA failed to increase paclitaxel effectiveness in all three cell lines. For comparison, the effects of other fatty acids on paclitaxel chemosensitivity were examined: GLA was the most potent at enhancing paclitaxel cytotoxicity, followed by alpha-linolenic acid (ALA; 18:3n.3), eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), whereas linoleic acid (LA; 18:2n-6) did not increase paclitaxel toxicity. These findings provide experimental support for the use of fatty acids as modulators of tumour cell chemosensitivity in paclitaxel-based therapy.

UI MeSH Term Description Entries
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D017239 Paclitaxel A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death. 7-epi-Taxol,Anzatax,Bris Taxol,NSC-125973,Onxol,Paclitaxel, (4 alpha)-Isomer,Paxene,Praxel,Taxol,Taxol A,7 epi Taxol,NSC 125973,NSC125973,Taxol, Bris
D017965 gamma-Linolenic Acid An omega-6 fatty acid produced in the body as the delta 6-desaturase metabolite of linoleic acid. It is converted to dihomo-gamma-linolenic acid, a biosynthetic precursor of monoenoic prostaglandins such as PGE1. (From Merck Index, 11th ed) Gamolenic Acid,gamma-Linolenic Acid, Ammonium Salt,gamma-Linolenic Acid, Cerium Salt,gamma-Linolenic Acid, Indium Salt,gamma-Linolenic Acid, Lithium Salt,gamma-Linolenic Acid, Potassium Salt,gamma-Linolenic Acid, Sodium Salt,gamma-Linolenic Acid, Zinc Salt,Acid, Gamolenic,Acid, gamma-Linolenic,gamma Linolenic Acid,gamma Linolenic Acid, Ammonium Salt,gamma Linolenic Acid, Cerium Salt,gamma Linolenic Acid, Indium Salt,gamma Linolenic Acid, Lithium Salt,gamma Linolenic Acid, Potassium Salt,gamma Linolenic Acid, Sodium Salt,gamma Linolenic Acid, Zinc Salt

Related Publications

J A Menéndez, and M del Mar Barbacid, and S Montero, and E Sevilla, and E Escrich, and M Solanas, and H Cortés-Funes, and R Colomer
January 1999, Advances in experimental medicine and biology,
J A Menéndez, and M del Mar Barbacid, and S Montero, and E Sevilla, and E Escrich, and M Solanas, and H Cortés-Funes, and R Colomer
November 1985, Prostaglandins, leukotrienes, and medicine,
J A Menéndez, and M del Mar Barbacid, and S Montero, and E Sevilla, and E Escrich, and M Solanas, and H Cortés-Funes, and R Colomer
January 1992, Anticancer research,
J A Menéndez, and M del Mar Barbacid, and S Montero, and E Sevilla, and E Escrich, and M Solanas, and H Cortés-Funes, and R Colomer
January 1994, Free radical biology & medicine,
J A Menéndez, and M del Mar Barbacid, and S Montero, and E Sevilla, and E Escrich, and M Solanas, and H Cortés-Funes, and R Colomer
October 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
J A Menéndez, and M del Mar Barbacid, and S Montero, and E Sevilla, and E Escrich, and M Solanas, and H Cortés-Funes, and R Colomer
January 1965, Hoppe-Seyler's Zeitschrift fur physiologische Chemie,
J A Menéndez, and M del Mar Barbacid, and S Montero, and E Sevilla, and E Escrich, and M Solanas, and H Cortés-Funes, and R Colomer
January 1997, Antiviral therapy,
J A Menéndez, and M del Mar Barbacid, and S Montero, and E Sevilla, and E Escrich, and M Solanas, and H Cortés-Funes, and R Colomer
April 1984, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
J A Menéndez, and M del Mar Barbacid, and S Montero, and E Sevilla, and E Escrich, and M Solanas, and H Cortés-Funes, and R Colomer
February 2000, Prostaglandins, leukotrienes, and essential fatty acids,
J A Menéndez, and M del Mar Barbacid, and S Montero, and E Sevilla, and E Escrich, and M Solanas, and H Cortés-Funes, and R Colomer
November 1985, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
Copied contents to your clipboard!